Sentences with word «vedotin»

Recent FDA approval of front - line brentuximab vedotin with chemotherapy in patients with stage III / IV Hodgkin lymphoma offers the first new treatment for this disease in over 40 years.

«Five - year survival data: Brentuximab vedotin may be curative in some with Hodgkin lymphoma: Phase II trial suggests therapy should be standard of care for patients facing relapsed or treatment - resistant Hodgkin lymphoma.»

«The FDA Breakthrough Therapy designation underscores the potential of enfortumab vedotin as a meaningful treatment for patients with locally advanced or metastatic urothelial cancer,» said Robert Lechleider, MD, the vice president of clinical development at Seattle Genetics, according to a press release.

Genmab's strategy is to use its growing royalty stream from Darzalex to invest in its next wave of medicines like cervical cancer drug tisotumab vedotin, which is being developed in a 50/50 partnership with Seattle Genetics.

The research team evaluated the combination of the biologic therapy brentuximab vedotin (Adcetris), a monoclonal antibody - drug conjugate, with the chemotherapy drug gemcitabine (Gemzar) in 42 pediatric and young - adult patients with Hodgkin lymphoma, the most common cancer in young people ages 15 to 29.

In general, not all patients respond to checkpoint inhibition, suggesting the need for other approaches, such as that pursued with enfortumab vedotin.

The researchers report that these two therapies together represent a highly active combination for refractory or relapsed Hodgkin lymphoma, with a complete response rate exceeding that seen with standard therapy or following administration of either brentuximab vedotin or gemcitabine alone.

This multinational Phase II study examines brentuximab vedotin (BV) in patients with Hodgkin lymphoma who relapsed after stem cell transplant.

«It is critical to note that nine of the complete response patients have been in remission for over five years after receiving only brentuximab vedotin,» said Dr. Chen, «The fact that these patients are doing so well, even five years out, provides a new perspective for prognosis.»

Five - year survival data published online in Blood, the Journal of the American Society of Hematology (ASH), suggest that the targeted therapy brentuximab vedotin may have cured some Hodgkin lymphoma patients whose disease has persisted despite receiving previous therapies.

The FDA granted accelerated approval to nivolumab (Opdivo), an anti-PD-1 checkpoint inhibitor, for patients with classical Hodgkin lymphoma (cHL) whose disease has relapsed or progressed after stem cell transplantation and the targeted antibody brentuximab vedotin (Adcetris).

The FDA has approved brentuximab vedotin (Adcetris) to treat adults with previously untreated stage III or IV cHL, in combination with chemotherapy.

Moreover, 18 % of the patients on the brentuximab vedotin — plus - AVD arm experienced disease progression, death, or began new therapy, compared with 22 % of the patients on the ABVD arm.

Those treated with brentuximab vedotin plus AVD were 23 % less likely to experience progression, death, or initiation of new therapy compared with those receiving ABVD.

Brentuximab vedotin is an antibody - drug conjugate that combines an anti-C30 antibody with the drug monmethyl auristatin E, allowing the antibody to direct the drug to a target CD30 on lymphoma cells.

The approval was based on a clinical trial comparing brentuximab vedotin plus conmbination chemotherapy (Adriamycin [doxorubicin], vinblastine and dacarbazine, or AVD) vs a chemotherapy - only regimen commonly used to treat cHL (AVD plus bleomycin, also known as ABVD).

Brentuximab vedotin was previously approved by the FDA to treat cHL after relapse, cHL after stem cell transplant when a patient is at a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after failure of other treatment, and primary cutaneous ALCL after failure of other treatment.

The first of these antibody - drug combinations, Adcetris (brentuximab vedotin), was approved by the FDA in 2011 to treat lymphoma.

The US Food and Drug Administration (FDA) has approved brentuximab vedotin (Adcetris) to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL), in combination with chemotherapy.

The US Food and Drug Administration (FDA) has granted a Breakthrough Therapy designation to an antibody - drug conjugate known as enfortumab vedotin.

«Achieving Breakthrough Therapy designation for enfortumab vedotin is another step forward in our goal to bring an additional option to patients who need it most,» said Steven Benner, MD, the senior vice president of oncology development at Astellas.

The targeted drug brentuximab vedotin (Adcetris ®)-- a monoclonal antibody linked to a chemotherapy drug — is approved to treat Hodgkin lymphoma in patients whose disease has failed to respond to other treatment and, as of August 2015, to prevent relapse following a stem cell transplant.

A phase II trial of brentuximab vedotin (anti-CD30 antibody - drug conjugate) in combination with chemotherapy and radiation therapy for younger patients with advanced Hodgkin lymphoma (NCT01920932).

A combination of complementary immunotherapy drugs brentuximab vedotin (Adcetris ®) and nivolumab (Opdivo ®) destroyed most cancer cells in 64 percent of patients with recurrent Hodgkin lymphoma, according to the results of an early - phase clinical trial led by Catherine M. Diefenbach, MD, assistant professor of medicine and director of the Clinical Lymphoma Program.

These observations led her and her colleagues to test whether drugs that spur the immune system to attack cancer cells, such as checkpoint inhibitors like nivolumab, would work well with the targeted chemotherapy agent brentuximab vedotin.

Tags: ASH, Alex Herrera, Blood, Hodgkin lymphoma, PD - 1, brentuximab vedotin, hodgkin lymphoma, immunotherapy, nivolumab

Herrera's latest work builds upon phase 1 study results that he presented at the 2016 ASH meeting, measuring the safety of brentuximab vedotin — an antibody - based treatment that targets delivery of chemotherapy only to Hodgkin lymphoma cells — combined with nivolumab, which works by blocking something called the PD - 1 immune checkpoint pathway that tumors often hijack to evade the immune system.